Intravenous Immunoglobulin (IVIG) Market

Report Description
Table of Contents

Report Description

The global intravenous immunoglobulin (IVIG) market size is estimated to be USD xx billion in 2021 and is expected to witness a CAGR of xx% during the forecast period. Rise in occurrence of immunodeficiency diseases is a key driver for the growth of the global intravenous immunoglobulin (IVIG) market. Additionally, growing adoption of immunoglobulin replacement therapy and increasing global geriatric population in the intravenous immunoglobulin (IVIG) market are some of the other drivers propelling the market growth. Nevertheless, high cost of immunoglobulin therapy, lengthy approval procedures for new technology launches and stringent regulatory framework are expected to restrain the global market growth.

Global Intravenous Immunoglobulin (IVIG) Market Size (USD Billion), 2021-2029

Source: Erevna Healthcare

By Application

Based on application, the market is segmented into myasthenia gravis, hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, primary immunodeficiency diseases, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. In 2021, the hypogammaglobulinemia segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is attributed to increase in cases of primary immunodeficiency diseases (PID) worldwide. Chronic inflammatory demyelinating polyneuropathy (CIDP) segment projected to grow at a profitable CAGR during the forecast period. This is attributed to the benefits associated with this segment such as minimally invasive, safe, and user-friendly treatment choices are the major factors driving the market.

By Route of Administration

Based on route of administration, the market is categorized into subcutaneous and intravenous. In 2021, the intravenous segment accounted for the substantial revenue share with lucrative CAGR during the forecast period. This is due to the major usage of intravenous immunoglobulins in an extensive array of immunology applications worldwide. The subcutaneous segment is anticipated to grow at a profitable CAGR during the forecast period, due to the increasing in use of subcutaneous IGs for the treatment of PIDs is expected to drive the market.

Regional Insights

In 2021, North America accounted for the highest revenue share in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the increase in awareness related to IVIG product used for treatment of immunodeficiency diseases, growth in initiatives from government, accessibility of technological advanced products in the region. Asia Pacific market is projected to exhibit the fastest CAGR over the forecast period owing to the changing lifestyle with increasing disposable income, growing government and corporate investment in healthcare sector, aged population, and increasing cases of immunodeficiency diseases, are the major factors in this region.

Competitor Insights

Some of the key players in the intravenous immunoglobulin (IVIG) market are Baxter International Inc. (U.S.); Bayer AG (Germany); Biotest AG (Germany); China Biologic Products, Inc. (China); CSL Limited (Australia);Grifols, S.A. (Spain); Kedrion Biopharma Inc. (U.S.); LFB Biotechnologies (France); Octapharma AG (Switzerland); and Takeda Pharmaceutical Company Limited (Japan). The leading players operating in the intravenous immunoglobulin (IVIG) industry are adopting various strategies including R&D investments, adaption of advanced techniques, new technology launches, mergers & acquisitions, and regional expansions to capture a maximum revenue share.

This exhaustive research report focuses on market size and forecast at global, segmental, regional and country level along with key market trends and dynamics from 2021 to 2029. The intravenous immunoglobulin (IVIG) market report is categorized into the following segments and subsegments: